India Pharma Outlook | Tuesday, 12 August 2025
Zydus Lifesciences reported its consolidated revenue of Rs 65,737 million for Q1 FY26, highlighting a 6 percent YoY increase, while net profit rose 3 percent to Rs 14,668 million. The company has a strong foundation and plays a substantial role in the Indian formulations business.
Alongside launching its new products in the US, it converted a 37 percent contribution to its sales in foreign markets and drove growth, which kept EBITDA steady at Rs 20,885 million. The company’s API division grew 11 percent YoY, and the consumer wellness division recorded a fair 2 percent increase.
In the quarter, the company advanced its innovation pipeline by initiating Phase II clinical trials for an ALS treatment, securing approvals for biosimilars and progressing vaccine development programs. Entering the global biologics CDMO marketspace through the acquisition of a US-based manufacturing facility and a stake in France’s Amplitude Surgical, a global leader in providing advanced lower limb orthopedic solutions.
From an operational point of view, API sites in Ankleshwar and Dabhasa have received operational excellence and compliance credentials from the USFDA. Emphasizing innovation, diversifying its specialty portfolio and leadership in chronic therapies as a foundation for the long-term run and sustainable growth in the global market, management reaffirmed its FY26 Growth targets.
